Skip to main content
48°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Glycomimetics Inc
(NQ:
GLYC
)
2.160
-0.120 (-5.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glycomimetics Inc
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 27, 2024
Via
Benzinga
GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023
March 27, 2024
GLYC stock results show that GlycoMimetics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
March 27, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Earnings Outlook For GlycoMimetics
March 26, 2024
Via
Benzinga
Earnings Outlook For GlycoMimetics
November 02, 2023
Via
Benzinga
GlycoMimetics: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
Earnings Scheduled For March 27, 2024
March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
Via
Benzinga
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
March 21, 2024
Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies.
Via
Talk Markets
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
March 13, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
February 26, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 12, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 24, 2024
Via
Benzinga
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
January 04, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Why Trinity Place Holdings Shares Are Trading Higher By 80%; Here Are 20 Stocks Moving Premarket
January 03, 2024
Shares of Trinity Place Holdings Inc. (NYSE: TPHS) rose sharply in pre-market trading. The company reported in 8K Filing, mortgage lender agreed to extend the mortgage loan forbearance period to Jan....
Via
Benzinga
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
January 03, 2024
From
Apollomics Inc.
Via
GlobeNewswire
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
December 10, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
November 09, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Earnings Scheduled For November 3, 2023
November 03, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
Via
Benzinga
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
November 03, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
October 20, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
September 06, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
August 02, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
July 19, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
June 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
June 15, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
May 31, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation
May 09, 2023
Blood cancers such as AML, MM, and MDS affect a terrible toll on patients and their loved ones. Glycomimetics may be such a company that can offer patients suffering from various blood cancers hope...
Via
Talk Markets
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.